Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967446 | 0.80 | MAPT (0.48) | CHRNB2CHRNA4ALDH1A1GAAMAPT | |
| SCHEMBL5416033 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4CYP11B2HTTCHRNA7 | |
| SCHEMBL3968908 | 0.73 | F2 (0.42) | GAAMAPTELANE | |
| SCHEMBL5408330 | 0.70 | CHRNB2 (0.55) | CHRNB2CHRNA4CYP11B2HTTCHRNA7 | |
| SCHEMBL5405408 | 0.69 | CHRNB2 (0.50) | CHRNB2CHRNA4CYP11B2HTTCHRNA7 | |
| SCHEMBL15553232 | 0.69 | CYP11B2 (0.42) | CYP11B2ALDH1A1GAAMAPTRECQL | |
| SCHEMBL3972627 | 0.69 | HTR3A (0.49) | ALDH1A1GAACYP3A4 | |
| SCHEMBL5729484 | 0.68 | CHRNB2 (0.57) | CHRNB2CHRNA4HTTCHRNA7CHRNB4 | |
| SCHEMBL7532910 | 0.68 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP3A4CYP2A6CHRNA7 | |
| SCHEMBL4283993 | 0.68 | POLB (0.46) | ALDH1A1GAAMAPTRECQLHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866656-B1 | USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS | MARGOLIN SOLOMON B (US) | 2007-04-25 | — | — | EP | claimed |
| EP-0813409-B1 | TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS | MARGOLIN SOLOMON B (US) | 2004-05-06 | — | — | EP | claimed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | claimed |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2023-05-18 | — | — | US | disclosed |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2022-07-14 | — | — | US | disclosed |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210346399-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | AVALYN PHARMA INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2012106382-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20060198823-A1 | Compositions and methods for treating viral infections | INTERMUNE, INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CHRNB2 4875/4885CHRNA4 4816/4885CYP11B2 1744/4885 |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CHRNB2 4875/4885CHRNA4 4816/4885CYP11B2 1744/4885 |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-20060198823-A1 | Compositions and methods for treating viral infections | IFNAR1, IFNG, TLR3 | CHRNB2 1991/4885CHRNA4 1350/4885CYP11B2 2181/4885 |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | CHRNB2 4875/4885CHRNA4 4816/4885CYP11B2 1744/4885 |
| US-20210346399-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | CHRNB2 969/4885CHRNA4 532/4885CYP11B2 1106/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CHRNB2 4875/4885CHRNA4 4816/4885CYP11B2 1744/4885 |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | PLPBP, PIR, PDXK | CHRNB2 1028/4885CHRNA4 553/4885CYP11B2 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.